Komori
Ensuiko Sugar Refining (2112) · FactWorsened

Revenue and Profit Growth in the Bio Business

First written in FY2017-Q1. 13 of 35 entries say "Worsened", first in FY2018-Q1. Latest entry: 2026-08-07.

35entries
11years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseWorsenedFY2023 – 2026-08-072016: 220162017: 320172018: 420182019: 420192020: 420202021: 420212022: 420222023: 420232024: 120242025: 220252026: 32026
Same theme, other companies
Revenue Fluctuations and Loss-to-Profit Turnaround in Biotech and Healthcare-Related BusinessesA theme 4 companies write about · 2 as a headwind · 1 as a tailwind

Ensuiko Sugar Refining moved to the "Worse" side of this theme in 2023, 6 years after the typical company in this theme (2017).

1 other company's latest entry also says "Worsened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. 2026-08-07WorsenedEarnings

    「ビーツ製品は、ECサイトでの販売強化に務めました結果、売上高は前年同四半期を上回りました。 以上の結果、バイオ事業全体の売上高は443百万円（前年同四半期比2.1％減）物価高に伴う生産コストの増加により、セグメント利益は92百万円（前年同四半期比9.7％減）となりました。」

    ビーツ製品とオリゴ糖製品の一部は増収となった一方、バイオ事業全体は減収減益で、物価高に伴う生産コスト増加が示されている。
  2. FY2026WorsenedAnnual report

    「Revenue for the Biotechnology Business as a whole was ¥1,603 million, down 1.3% from the previous consolidated fiscal year, while segment profit was ¥282 million, down 10.7%.」

    The Biotechnology Business posted declines in both revenue and profit for the full year, with revenue down 1.3% and segment profit down 10.7%.
  3. 2026-05-08WorsenedEarnings

    「バイオ事業全体の売上高は1,603百万円（前連結会計年度比1.3％減）、セグメント利益は282百万円（前連結会計年度比10.7％減）となりました」

    バイオ事業は減収減益が続いている。
  4. FY2026-H1WorsenedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥847 million, up 1.0% from the previous interim consolidated accounting period, while segment profit was ¥160 million, down 14.2% due to higher raw material costs and other factors.」

    Revenue in the Biotechnology Business increased 1.0%, while segment profit declined 14.2% due to higher raw material costs and other factors, continuing the decline in profit.
  5. FY2025WorsenedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥1,625 million, down 11.5% from the previous consolidated fiscal year, while segment profit was ¥316 million, down 23.3%.」

    The Biotechnology Business posted declines in both revenue and profit for the full year, with both falling below the previous year. In particular, the decline in profit widened from 11.6% in the interim period to 23.3%.
  6. FY2025-H1WorsenedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥838 million, down 13.1% from the previous interim consolidated accounting period, while segment profit was ¥186 million, down 11.6% due to higher raw material costs and other factors.」

    The Biotechnology Business posted declines in both revenue and profit for the interim cumulative period, with revenue down 13.1% and segment profit down 11.6%, partly due to higher raw material costs and other factors.
  7. FY2024-Q2WorsenedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥964 million, up 4.3% from the same quarter of the previous year, while segment profit was ¥211 million, down 11.3% due to higher raw material costs and other factors.」

    The Biotechnology Business posted higher revenue, while segment profit declined 11.3% due to higher raw material costs and other factors.
  8. FY2024-Q1WorsenedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥514 million, up 4.8% from the same quarter of the previous year, while segment profit was ¥114 million, down 16.6% due to higher raw material costs and other factors.」

    The Biotechnology Business posted higher revenue, while segment profit declined 16.6% due to higher raw material costs and other factors.
  9. FY2023WorsenedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥1,790 million, down 2.3% from the previous consolidated fiscal year, while segment profit was ¥424 million, down 13.7%.」

    The Biotechnology Business posted declines in both revenue and profit for the full year.
  10. FY2023-Q3Flat revenue and lower profit following the reversal of special demandAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥1,407 million, down 0.1% from the same quarter of the previous year, while segment profit was ¥354 million, down 8.2%.」

    Revenue in the Biotechnology Business declined 0.1% and segment profit declined 8.2% year on year, with declines in both revenue and profit continuing, although the declines narrowed from the previous quarter.
  11. FY2023-Q2WorsenedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥925 million, down 1.5% from the same quarter of the previous year, while segment profit was ¥238 million, down 10.0%.」

    Revenue in the Biotechnology Business declined 1.5% from the same quarter of the previous year and segment profit declined 10.0%, resulting in declines in both revenue and profit.
  12. FY2023-Q1AdvancedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥491 million, up 6.0% from the same quarter of the previous year, while segment profit was ¥137 million, up 7.4%.」

    Revenue in the Biotechnology Business increased 6.0% and segment profit increased 7.4%, progressing from profit growth despite lower revenue in the same period of the previous year to growth in both revenue and profit.
  13. FY2022AdvancedAnnual report

    「Revenue for the Biotechnology Business as a whole was ¥1,833 million, down 3.4% from the previous consolidated fiscal year, while segment profit was ¥491 million, up 28.5%.」

    The Biotechnology Business continued to achieve profit growth despite lower revenue, with the increase in profit widening from 0.8% in the previous fiscal year to 28.5%.
  14. FY2022-Q3Sustained and widening profit growth despite lower revenueAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥1,409 million, down 3.9% from the same quarter of the previous year, while segment profit was ¥386 million, up 26.4%.」

    Revenue in the Biotechnology Business declined 3.9%, while segment profit increased 26.4%, sustaining profit growth despite lower revenue.
  15. FY2022-Q2AdvancedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥939 million, down 0.3% from the same quarter of the previous year, while segment profit was ¥264 million, up 30.7%.」

    The year-on-year decline in revenue narrowed to 0.3%, while segment profit increased 30.7%.
  16. FY2022-Q1Profit Growth Despite Revenue DeclineAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥463 million, down 4.8% from the same quarter of the previous year, while segment profit was ¥127 million, up 20.5%.」

    Revenue in the Biotechnology Business declined 4.8% from the same quarter of the previous year, while segment profit increased 20.5%.
  17. FY2021AdvancedAnnual report

    「Revenue for the Biotechnology Business as a whole was ¥1,897 million, up 6.6% from the previous consolidated fiscal year, while segment profit was ¥382 million, up 32.9%.」

    The Biotechnology Business posted growth in both revenue and profit for the full year, achieving a 6.6% increase in revenue and a 32.9% increase in segment profit.
  18. FY2021-Q3AdvancedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥1,466 million, up 5.4% from the same quarter of the previous year, while segment profit was ¥305 million, up 20.1%.」

    Both revenue and segment profit in the Biotechnology Business exceeded those of the same quarter of the previous year, sustaining growth in both revenue and profit.
  19. FY2021-Q2AdvancedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥941 million, up 3.7% from the same quarter of the previous year, while segment profit was ¥202 million, up 15.4%.」

    Revenue in the Biotechnology Business increased 3.7% and segment profit increased 15.4%, sustaining growth in both revenue and profit.
  20. FY2021-Q1AdvancedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥486 million, up 6.7% from the same quarter of the previous year, while segment profit was ¥106 million, up 21.2%.」

    Both revenue and segment profit in the Biotechnology Business exceeded those of the same quarter of the previous year, progressing from a full-year revenue decline in the previous fiscal year to growth in both revenue and profit.
  21. FY2020Profit growth despite a full-year revenue declineAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥1,780 million, down 2.1% from the previous consolidated fiscal year, while segment profit was ¥287 million, up 0.8%.」

    The Biotechnology Business posted a full-year revenue decline, while segment profit increased 0.8%.
  22. FY2020-Q3Profit growth continued despite lower revenueAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥1,390 million, down 0.7% year on year, while segment profit was ¥254 million, up 11.4%.」

    Revenue in the Biotechnology Business declined 0.7%, while segment profit increased 11.4%, resulting in higher profit despite lower revenue.
  23. FY2020-Q2Profit Growth Despite Revenue DeclineAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥908 million, down 1.5% year on year, while segment profit was ¥175 million, up 11.0%.」

    Revenue in the Biotechnology Business declined 1.5%, while segment profit increased 11.0%, resulting in lower revenue but higher profit.
  24. FY2020-Q1WorsenedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥455 million, down 5.3% year on year, while segment profit was ¥87 million, down 3.7%.」

    Both revenue and segment profit in the Biotechnology Business fell below the same period of the previous year, turning from profit growth despite a full-year revenue decline in the previous fiscal year to declines in both revenue and profit.
  25. FY2019Profit growth despite a full-year revenue declineAnnual report

    「Revenue for the Biotechnology Business as a whole was ¥1,818 million, down 0.4% from the previous consolidated fiscal year, while segment profit was ¥285 million, up 14.0%.」

    For the full year, revenue declined 0.4%, while segment profit increased 14.0%.
  26. FY2019-Q3Higher Earnings Despite Lower RevenueAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥1,401 million, down 1.1% year on year, while segment profit was ¥228 million, up 12.0%.」

    Revenue in the Biotechnology Business fell 1.1% year on year, while segment profit increased 12.0%.
  27. FY2019-Q2AdvancedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥922 million, up 0.3% from the same quarter of the previous year, while segment profit was ¥158 million, up 18.6%.」

    Revenue in the Biotechnology Business increased 0.3% year on year and segment profit increased 18.6%, sustaining growth in both revenue and profit.
  28. FY2019-Q1AdvancedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥481 million, up 0.1% year on year, while segment profit was ¥91 million, up 8.4%.」

    Following declines in both revenue and profit in the previous fiscal year, revenue turned to a 0.1% increase and segment profit to an 8.4% increase.
  29. FY2018Continued revenue and earnings decline; narrower earnings declineAnnual report

    「As a result, revenue for the Biotechnology Business as a whole was ¥1,824 million, down 3.1% from the previous consolidated fiscal year, while segment profit was ¥250 million, down 29.4%.」

    The Biotechnology Business posted declines in both revenue and profit for the full year, although the declines narrowed from the previous quarter's 6.5% decrease in revenue and 40.0% decrease in profit.
  30. FY2018-Q3Continued revenue and earnings decline; narrower earnings declineAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥1,416 million, down 4.0% year on year, while segment profit was ¥203 million, down 34.7%.」

    Both revenue and segment profit in the Biotechnology Business fell below the same period of the previous year. The declines narrowed from the previous quarter's 6.5% decrease in revenue and 40.0% decrease in profit, but the declines in both revenue and profit continued.
  31. FY2018-Q2WorsenedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥919 million, down 6.5% from the same quarter of the previous year, while segment profit was ¥133 million, down 40.0%.」

    Both revenue and segment profit in the Biotechnology Business fell below the same period of the previous year, with the declines widening.
  32. FY2018-Q1WorsenedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥480 million, down 5.8% year on year, while segment profit was ¥83 million, down 32.0%.」

    Both revenue and segment profit in the Biotechnology Business fell below the same period of the previous year, turning to declines from the growth trend through the previous quarter.
  33. FY2017-Q3RestatedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥1,475 million, up 14.4% year on year, while segment profit was ¥287 million, up 127.4%.」

    The Biotechnology Business continued to show a growth trend, with revenue and segment profit exceeding those of the same period of the previous year.
  34. FY2017-Q2RestatedAnnual report

    「As a result, revenue for the Biotechnology Business as a whole for the period was ¥984 million, up 18.0% from the same quarter of the previous year, while segment profit was ¥204 million, up 162.4%.」

    The Biotechnology Business continued to show a growth trend, with revenue and segment profit exceeding those of the same period of the previous year.
  35. FY2017-Q1First statedAnnual report

    「Revenue for the Biotechnology Business as a whole was ¥510 million, up 22.6% year on year, while segment profit was ¥123 million, up 230.5%.」

    The Biotechnology Business's year-on-year growth in revenue and segment profit is reported as actual performance.
Moved together

"Yen Appreciation and Economic Downturn Driven by China's Economic Slowdown, Brexit and Other Factors" moved the same way as this thread, in the same document, in 11 of its 35 moves.

1198776★123456
  1. ★This thread
  2. 1Yen Appreciation and Economic Downturn Driven by China's Economic Slowdown, Brexit and Other Factors11×
  3. 2Debt Guarantees for 太平洋製糖9×
  4. 3Market Value Fluctuation Risk of Marketable Securities8×
  5. 4Exposure to Overseas Raw and Brown Sugar Market Conditions and Weather Variability in Major Producing Countries7×
  6. 5Decline in Equity-Method Investment Profit7×
  7. 6Expansion of sales in the oligosaccharide business6×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Ensuiko Sugar Refining's next results are scheduled for 2026-11-06. Read the earnings preview It last moved in the Earnings of 2026-08-07: "Worsened".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Revenue and Profit Growth in the Bio Business | Ensuiko Sugar Refining Co.,Ltd. (2112) | Komori